Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells
Cancer Communications · 2024
DOI: 10.1002/cac2.12546 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Communications, 2024. Verfasst von Yijia Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China. Hauptthemen laut MEDLINE: Immunotherapy, Epigenesis, Genetic, Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 323 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Nature Science Foundation of Hunan Province.
Abstract (Originalsprache)
Significant developments in cancer treatment have been made since the advent of immune therapies. However, there are still some patients with malignant tumors who do not benefit from immunotherapy. Tumors without immunogenicity are called “cold” tumors which are unresponsive to immunotherapy, and the opposite are “hot” tumors. Immune suppressive cells (ISCs) refer to cells which can inhibit the immune response such as tumor‐associated macrophages (TAMs), myeloid‐derived suppressor cells (MDSCs), regulatory T (Treg) cells and so on. The more ISCs infiltrated, the weaker the immunogenicity of the tumor, showing the characteristics of “cold” tumor. The dysfunction of ISCs in the tumor microenvironment (TME) may play essential roles in insensitive therapeutic reaction. Previous studies have found that epigenetic mechanisms play an important role in the regulation of ISCs. Regulating ISCs may be a new approach to transforming “cold” tumors into “hot” tumors. Here, we focused on the function of ISCs in the TME and discussed how epigenetics is involved in regulating ISCs. In addition, we summarized the mechanisms by which the epigenetic drugs convert immunotherapy‐insensitive tumors into immunotherapy‐sensitive tumors which would be an innovative tendency for future immunotherapy in “cold” tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
- National Clinical Resaerch Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
ORCID-Profile: Ziyang Feng, Shan Zeng
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Nature Science Foundation of Hunan Province
- Nature Science Foundation of Changsha
- CSCO Cancer Research Foundation
- the Key Research and Development Program of Hainan Province
Zitieren
APA
Tang, Y., Cui, G., Liu, H., Han, Y., Cai, C., Feng, Z., Shen, H., & Zeng, S. (2024). Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells. Cancer Communications. https://doi.org/10.1002/cac2.12546
Vancouver
Tang Y, Cui G, Liu H, Han Y, Cai C, Feng Z, et al. Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells. Cancer Communications. 2024. doi:10.1002/cac2.12546
BibTeX
@article{Tang2024,
author = {Tang, Yijia and Cui, Guangzu and Liu, Haicong and Han, Ying and Cai, Changjing and Feng, Ziyang and Shen, Hong and Zeng, Shan},
title = {Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells},
journal = {Cancer Communications},
year = {2024},
doi = {10.1002/cac2.12546}
}
EUVIMED